Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics


Press Release

Novato, CA, U.S., June 24, 2022 – Announcing our corporate name change and new branding.

We’re excited to announce that Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics.

We remain exactly on track to commence human clinical trials for UDP-003 in 2023. Now at the halfway point of 2022, the closer we get to this critical goal, the more exciting things have become here. Unfortunately, it has raised one significant problem for us:

In the race to cure atherosclerosis, it’s getting hard to refer to ourselves as the “Underdog!”

So we met with the Board, talked to select stakeholders and PR professionals (and a lawyer or two), and asked our shareholders to approve a new corporate name, the brand under which our team will strive to cure heart disease and to make our mark in the field of aging. We strove to connote vision, and to reference the clearance of toxic oxysterols and other by-products of aging that will remain our focus. So, welcome, all, to Cyclarity.

We have been fortunate to have the unwavering support of Kizoo Technology Ventures as our lead investor, and all of your support as our shareholders, collaborators and friends. Your clarity of vision helped get us this far, and we look forward now, with Cyclarity, to the commencement of human trials for what may be one of the most important rejuvenation drugs in development. Thank you.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.


Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics logos for media use:

Cyclarity News:

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Read More »

Kizoo Portfolio Company Underdog Closes $10M Financing Round

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.

Underdog was recently awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.

Read More »